Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study.
Colectomy
Colorectal cancer
Inflammatory bowel disease
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
23
07
2020
accepted:
10
01
2021
pubmed:
10
2
2021
medline:
17
11
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
The extent of surgical resection in inflammatory bowel disease (IBD) patients who develop colorectal cancer (CRC) is not prescribed by guidelines. We aim to evaluate, at a population level, the association of extent of surgical resection with survival outcomes. Using a validated Ontario registry of Crohn's disease (CD) and ulcerative colitis (UC) patients, we identified patients who underwent colorectal cancer resection between 2007 and 2015. Patient, tumor, and treatment factors, including type of surgical resection, were collected. Resections were grouped as segmental, total colectomy, and proctocolectomy. Multivariable cox proportional hazard regression was performed to identify factors associated with survival, including extent of surgical resection. Between 2007 and 2015, 84,694 patients had resections for CRC in the province of Ontario, 599 had ulcerative colitis (UC), and 366 had Crohn's disease (CD). Segmental resection was the most common operation performed and was more common in CD patients compared to UC (68% vs. 45.6%, p < 0.001). Five-year survival was 63.7% (95% CI 59.5-67.7) in UC patients and 57.5% (95% CI 51.9-62.7) in CD patients (p = 0.033). Multivariable analysis showed worse survival in patients undergoing total colectomy, compared to segmental resection [HR 1.70 (95% CI 1.31-2.21), p < 0.001]. There was no significant difference in survival between patients undergoing segmental resection and proctocolectomy [HR 0.99 (95% CI 0.78-1.27)]. This pattern was similar within the subtypes of IBD. In the setting of IBD-associated CRC, segmental resection and proctocolectomy are associated with similar survival outcomes in both UC and CD patients. Prospective study is essential to explore these findings.
Sections du résumé
BACKGROUND
The extent of surgical resection in inflammatory bowel disease (IBD) patients who develop colorectal cancer (CRC) is not prescribed by guidelines. We aim to evaluate, at a population level, the association of extent of surgical resection with survival outcomes.
METHODS
Using a validated Ontario registry of Crohn's disease (CD) and ulcerative colitis (UC) patients, we identified patients who underwent colorectal cancer resection between 2007 and 2015. Patient, tumor, and treatment factors, including type of surgical resection, were collected. Resections were grouped as segmental, total colectomy, and proctocolectomy. Multivariable cox proportional hazard regression was performed to identify factors associated with survival, including extent of surgical resection.
RESULTS
Between 2007 and 2015, 84,694 patients had resections for CRC in the province of Ontario, 599 had ulcerative colitis (UC), and 366 had Crohn's disease (CD). Segmental resection was the most common operation performed and was more common in CD patients compared to UC (68% vs. 45.6%, p < 0.001). Five-year survival was 63.7% (95% CI 59.5-67.7) in UC patients and 57.5% (95% CI 51.9-62.7) in CD patients (p = 0.033). Multivariable analysis showed worse survival in patients undergoing total colectomy, compared to segmental resection [HR 1.70 (95% CI 1.31-2.21), p < 0.001]. There was no significant difference in survival between patients undergoing segmental resection and proctocolectomy [HR 0.99 (95% CI 0.78-1.27)]. This pattern was similar within the subtypes of IBD.
CONCLUSION
In the setting of IBD-associated CRC, segmental resection and proctocolectomy are associated with similar survival outcomes in both UC and CD patients. Prospective study is essential to explore these findings.
Identifiants
pubmed: 33559097
doi: 10.1007/s11605-021-04913-6
pii: 10.1007/s11605-021-04913-6
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2610-2618Informations de copyright
© 2021. The Society for Surgery of the Alimentary Tract.
Références
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Meta-Analysis Research Support, Non-U.S. Gov't. Gut. 2001;48(4):526-35.
doi: 10.1136/gut.48.4.526
Dulai PS, Sandborn WJ, Gupta S. Colorectal cancer and dysplasia in inflammatory bowel disease: A review of disease Epidemiology, Pathophysiology, and Management. Review. Cancer Prevention Research. December 2016;9(12):87-894.
Gillen CD, Andrews HA, Prior P, Allan RN. Crohn’s disease and colorectal cancer. Gut. May 1994;35(5):651-5.
doi: 10.1136/gut.35.5.651
Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. Nov 1994;35(11):1590-2.
doi: 10.1136/gut.35.11.1590
Brackmann S, Aamodt G, Andersen SN, et al. Widespread but not localized neoplasia in inflammatory bowel disease worsens the prognosis of colorectal cancer. Inflamm Bowel Dis. Mar 2010;16(3):474-81. https://doi.org/10.1002/ibd.21053
doi: 10.1002/ibd.21053
pubmed: 19714748
Brackmann S, Andersen SN, Aamodt G, et al. Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bowel Dis. Jan 2009;15(1):9-16. https://doi.org/10.1002/ibd.20542
doi: 10.1002/ibd.20542
pubmed: 18618636
Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. Aug 2014;20(29):9872-81. https://doi.org/10.3748/wjg.v20.i29.9872
doi: 10.3748/wjg.v20.i29.9872
pubmed: 25110418
pmcid: 4123369
Robles AI, Traverso G, Zhang M, et al. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology. Apr 2016;150(4):931-43. https://doi.org/10.1053/j.gastro.2015.12.036
doi: 10.1053/j.gastro.2015.12.036
pubmed: 26764183
Bogach J, Pond G, Eskicioglu C, Seow H. Age-Related Survival Differences in Patients With Inflammatory Bowel Disease-Associated Colorectal Cancer: A Population-Based Cohort Study. Inflamm Bowel Dis. Nov 2019;25(12):1957-1965. https://doi.org/10.1093/ibd/izz088
doi: 10.1093/ibd/izz088
pubmed: 31066449
Ording AG, Horvath-Puho E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn’s disease: a nationwide population-based cohort study. Inflammatory bowel diseases. 2013;19(4):800-805.
doi: 10.1097/MIB.0b013e3182802af7
Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. World J Gastroenterol. Aug 2019;25(30):4148-4157. https://doi.org/10.3748/wjg.v25.i30.4148
doi: 10.3748/wjg.v25.i30.4148
pubmed: 31435169
pmcid: 6700690
Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. Nov 2015;9(11):945-65. https://doi.org/10.1093/ecco-jcc/jjv141
doi: 10.1093/ecco-jcc/jjv141
pubmed: 26294789
Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. Dec 2013;7(12):982-1018. https://doi.org/10.1016/j.crohns.2013.09.016
doi: 10.1016/j.crohns.2013.09.016
pubmed: 24184171
Kornbluth A, Sachar DB, Gastroenterology PPCotACo. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. Mar 2010;105(3):501-23; quiz 524. https://doi.org/10.1038/ajg.2009.727
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 03 2019;114(3):384-413. https://doi.org/10.14309/ajg.0000000000000152
doi: 10.14309/ajg.0000000000000152
pubmed: 30840605
Maser EA, Sachar DB, Kruse D, Harpaz N, Ullman T, Bauer JJ. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn’s colitis. Inflamm Bowel Dis. Aug 2013;19(9):1827-32. https://doi.org/10.1097/MIB.0b013e318289c166
doi: 10.1097/MIB.0b013e318289c166
pubmed: 23669402
Network NCC. Colon Cancer. Accessed March 24 2018, https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
Vogel M, Eskicioglu C, Weiser M, Feingold D, Steele S. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer. In: Surgeons CPGCoTASoCaR, editor. Diseases of the Colon and Rectum2017. p. 999-1017.
Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Drugs and Aging. 01 Nov 2017;34(11):859-868.
doi: 10.1007/s40266-017-0498-y
IC/ES. IC/ES. https://www.ices.on.ca/
Benchimol EI, Guttmann A, Mack DR, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. J Clin Epidemiol. Aug 2014;67(8):887-96. https://doi.org/10.1016/j.jclinepi.2014.02.019
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. Jun 1992;45(6):613-9.
doi: 10.1016/0895-4356(92)90133-8
Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC Cancer Staging Manual. 7 ed. Springer-Verlag; 2010.
Raj KP, Taylor TH, Wray C, Stamos MJ, Zell JA. Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis. J Carcinog. Mar 2011;10:6. https://doi.org/10.4103/1477-3163.78114
doi: 10.4103/1477-3163.78114
pubmed: 21483654
pmcid: 3072650
Green R, Metlay J, Propert K, et al. Surveillance for a second primary colorectal cancer after adjuvant chemotherapy: An Analysis of Intergroup 0089. Annals of Internal Medicine; 2002. p. 261-269.
Tebala GD, Natili A, Gallucci A, et al. Emergency treatment of complicated colorectal cancer. Cancer Manag Res. 2018;10:827-838. https://doi.org/10.2147/CMAR.S158335
doi: 10.2147/CMAR.S158335
pubmed: 29719419
pmcid: 5916257
Ghazi S, Berg E, Lindblom A, Lindforss U, Group L-RCCS. Clinicopathological analysis of colorectal cancer: a comparison between emergency and elective surgical cases. World J Surg Oncol. Jun 2013;11:133. https://doi.org/10.1186/1477-7819-11-133
doi: 10.1186/1477-7819-11-133
pubmed: 23758762
pmcid: 3687686
Wong SK, Jalaludin BB, Morgan MJ, et al. Tumor pathology and long-term survival in emergency colorectal cancer. Dis Colon Rectum. Feb 2008;51(2):223-30. https://doi.org/10.1007/s10350-007-9094-2
doi: 10.1007/s10350-007-9094-2
pubmed: 18097722
Hogan J, Samaha G, Burke J, et al. Emergency presenting colon cancer is an independent predictor of adverse disease-free survival. Int Surg. Jan 2015;100(1):77-86. https://doi.org/10.9738/INTSURG-D-13-00281.1
doi: 10.9738/INTSURG-D-13-00281.1
pubmed: 25594643
pmcid: 4301297
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. Nov 2009;361(21):2066-78. https://doi.org/10.1056/NEJMra0804647
doi: 10.1056/NEJMra0804647
pubmed: 19923578
pmcid: 3491806
Khan N, Cole E, Shah Y, Paulson EC. Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. Colorectal Dis. Dec 2017;19(12):1108-1116. https://doi.org/10.1111/codi.13721
doi: 10.1111/codi.13721
pubmed: 28498617
Krugliak Cleveland N, Ollech JE, Colman RJ, et al. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 01 2019;17(1):205-206. https://doi.org/10.1016/j.cgh.2018.04.061
doi: 10.1016/j.cgh.2018.04.061
pubmed: 29751167